'Fast Money' Recap: A Risky Market for Investors

If he had control of the stimulus package, he said he would initiate an income tax holiday for six months. "Can you imagine the boom we would have in that six-month period?"

Ratigan brought in Mick Huckman, a CNBC reporter, to talk about the prospects for biopharma stocks in 2009. Huckman said the report today of a deal by Endo Pharma(ENDP Quote) to buy Indevus Pharma(IDEV Quote) for something in the range of $4.50 a share to $7.50 a share is a harbinger of what could be a record year for mergers and acquisitions and partnership deals in biopharma.

He said it's happening because large biopharmas are facing patent expirations with little in the pipeline to fill the hole. Meanwhile, small biopharmas are running short of cash.

Finerman agreed with the theory but didn't know which ones were the best merger opportunities.

Huckman ticked off some names like Gilead Sciences (GILD Quote) and Onyx Pharmaceuticals(ONXX Quote).

He also said to look out for a company called Orexigen Therapeutics(OREX Quote), which, he said, is coming out this week or next with the first data on late-stage results of a weight-loss drug.